Latin American consensus on guidelines for chronic migraine treatment.

Chronic migraine is a condition with significant prevalence all around the world and high socioeconomic impact, and its handling has been challenging neurologists. Developments for understanding its mechanisms and associated conditions, as well as that of new therapies, have been quick and important, a fact which has motivated the Latin American and Brazilian Headache Societies to prepare the present consensus. The treatment of chronic migraine should always be preceded by a careful diagnosis review; the detection of possible worsening factors and associated conditions; the stratification of seriousness/impossibility to treat; and monitoring establishment, with a pain diary. The present consensus deals with pharmacological and nonpharmacological forms of treatment to be used in chronic migraine.

[1]  T. Steiner,et al.  Health-care utilization for primary headache disorders in China: a population-based door-to-door survey , 2013, The Journal of Headache and Pain.

[2]  J. Saper,et al.  Topiramate for migraine prevention: a randomized controlled trial. , 2004, JAMA.

[3]  P. Kowacs,et al.  Hospital management of intractable headaches. The Instituto de Neurologia de Curitiba approach , 2011 .

[4]  P. Monzillo,et al.  [Acute treatment of migraine in emergency room: comparative study between dexametasone and haloperidol. Preliminary results]. , 2004, Arquivos de neuro-psiquiatria.

[5]  S. Silberstein,et al.  Safety of Divalproex Sodium in Migraine Prophylaxis: An Open‐Label, Long‐term Study , 1999, Headache.

[6]  M. Bigal,et al.  Temporomandibular Disorders Are Differentially Associated With Headache Diagnoses: A Controlled Study , 2011, The Clinical journal of pain.

[7]  S. Silberstein,et al.  Defining the Pharmacologically Intractable Headache for Clinical Trials and Clinical Practice , 2010, Headache.

[8]  M. van Buchem,et al.  Migraine is associated with an increased risk of deep white matter lesions, subclinical posterior circulation infarcts and brain iron accumulation: The population-based MRI CAMERA study , 2010, Cephalalgia : an international journal of headache.

[9]  M. Obermann,et al.  Management of medication-overuse headache , 2007, Expert review of neurotherapeutics.

[10]  L. Crevits,et al.  Practical management of medication-overuse headache. , 2006, Acta neurologica Belgica.

[11]  R. Lipton,et al.  Habitual snoring as a risk factor for chronic daily headache , 2003, Neurology.

[12]  E. Cook,et al.  Lack of Association Between Migraine Headache and Patent Foramen Ovale: Results of a Case-Control Study , 2010, Circulation.

[13]  E. Lauterbach,et al.  Psychiatric comorbidities of chronic migraine in community and tertiary care clinic samples , 2012, The Journal of Headache and Pain.

[14]  R. Lipton,et al.  Major Life Changes Before and After the Onset of Chronic Daily Headache: A Population-Based Study , 2008, Cephalalgia : an international journal of headache.

[15]  B. Klapp,et al.  Somatic comorbidities of irritable bowel syndrome: a systematic analysis. , 2008, Journal of psychosomatic research.

[16]  N. Mathew,et al.  A Double‐Blind Comparison of OnabotulinumtoxinA (BOTOX®) and Topiramate (TOPAMAX®) for the Prophylactic Treatment of Chronic Migraine: A Pilot Study , 2009, Headache.

[17]  W. Young,et al.  Neuroleptics and migraine. , 2009, Central nervous system agents in medicinal chemistry.

[18]  A. Krymchantowski,et al.  An open pilot study assessing the benefits of quetiapine for the prevention of migraine refractory to the combination of atenolol, nortriptyline, and flunarizine. , 2010, Pain medicine.

[19]  R. Lipton,et al.  Why headache treatment fails , 2003, Neurology.

[20]  M. Stokes,et al.  Cost of Health Care Among Patients With Chronic and Episodic Migraine in Canada and the USA: Results From the International Burden of Migraine Study (IBMS) , 2011, Headache.

[21]  S. Khuder,et al.  Depression and Anxiety: Effect on the Migraine–Obesity Relationship , 2007, Headache.

[22]  S. Nazarian,et al.  Migraine headache and ischemic stroke risk: an updated meta-analysis. , 2010, The American journal of medicine.

[23]  H. Diener.  Detoxification for medication overuse headache is not necessary , 2012, Cephalalgia : an international journal of headache.

[24]  S. Silberstein,et al.  Fibromyalgia is common in patients with transformed migraine , 2001, Neurology.

[25]  R. Lipton,et al.  The Global Burden of Headache: A Documentation of Headache Prevalence and Disability Worldwide , 2007, Cephalalgia : an international journal of headache.

[26]  C. Lundqvist,et al.  Management of primary chronic headache in the general population: the Akershus study of chronic headache , 2011, The Journal of Headache and Pain.

[27]  T. Steiner,et al.  The Prevalence and Burden of Primary Headaches in China: A Population‐Based Door‐to‐Door Survey , 2012, Headache.

[28]  G. Tabeeva,et al.  Topiramate in the Treatment of Chronic Migraine , 2014, Neuroscience and Behavioral Physiology.

[29]  C. Lundqvist,et al.  Management of secondary chronic headache in the general population: the Akershus study of chronic headache , 2012, The Journal of Headache and Pain.

[30]  H. Diener,et al.  Incidence and predictors for chronicity of headache in patients with episodic migraine , 2004, Neurology.

[31]  H. Diener,et al.  Prednisone vs. Placebo in Withdrawal Therapy Following Medication Overuse Headache , 2008, Cephalalgia : an international journal of headache.

[32]  J. Tembl,et al.  Migraine, patent foramen ovale and migraine triggers , 2007, The Journal of Headache and Pain.

[33]  John Weiner,et al.  Letter to the Editor , 1992, SIGIR Forum.

[34]  S. Silberstein,et al.  Topiramate in Migraine Prevention: Results of a Large Controlled Trial , 2004 .

[35]  Hae-Eun Shin,et al.  Differences in Clinical Features and Disability according to the Frequency of Medication Use in Patients with Chronic Migraine , 2012, Journal of clinical neurology.

[36]  H. Neuhauser,et al.  Epidemiological evidence for a link between vertigo and migraine. , 2011, Journal of vestibular research : equilibrium & orientation.

[37]  R. Lipton,et al.  Global prevalence of chronic migraine: A systematic review , 2010, Cephalalgia : an international journal of headache.

[38]  R. Ross,et al.  Intravenous Chlorpromazine ‐ Preliminary Results In Acute Migraine , 1985, Headache.

[39]  T. Bartsch,et al.  Medication overuse headache , 2006, MMW Fortschritte der Medizin.

[40]  P. Goadsby,et al.  Neurobiology of migraine , 2009, Neuroscience.

[41]  M. Brin,et al.  OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double‐Blind, Randomized, Placebo‐Controlled Phases of the PREEMPT Clinical Program , 2010, Headache.

[42]  J. Frampton.  OnabotulinumtoxinA (BOTOX®) , 2012, Drugs.

[43]  S. Aurora.  Response to “OnabotulinumtoxinA for the treatment of chronic migraine not quite there. . .” , 2011, Cephalalgia : an international journal of headache.

[44]  M. Allena,et al.  From drug-induced headache to medication overuse headache. A short epidemiological review, with a focus on Latin American countries , 2009, The Journal of Headache and Pain.

[45]  W. Stewart,et al.  Acute Migraine Medications and Evolution From Episodic to Chronic Migraine: A Longitudinal Population‐Based Study , 2008, Headache.

[46]  P. Cortelli,et al.  Chronic daily headache: risk factors and pathogenetic considerations , 2006, Neurological Sciences.

[47]  F. Sheftell,et al.  Discontinuation of Medication Overuse in Headache Patients: Recovery of Therapeutic Responsiveness , 2007, Cephalalgia : an international journal of headache.

[48]  J. Olesen,et al.  New Appendix Criteria Open for a Broader Concept of Chronic Migraine , 2006, Cephalalgia : an international journal of headache.

[49]  Paulo Hélio Monzillo,et al.  Tratamento agudo da crise de enxaqueca refratária na emergência: estudo comparativo entre dexametasona e haloperidol. Resultados preliminares , 2004 .

[50]  M. Bigal,et al.  Chronic Pain and Depression in the Quality of Life of Women With Migraine – A Controlled Study , 2012, Headache.

[51]  Frequency of types of headache in the tertiary care center of the Hospital das Clínicas of the Universidade Federal de Minas Gerais, MG, Brazil. , 2012, Revista da Associacao Medica Brasileira.

[52]  R. Hering,et al.  Sodium Valproate in The Prophylactic Treatment of Migraine: A Double-Blind Study Versus Placebo , 1992, Cephalalgia : an international journal of headache.

[53]  P. Rossi,et al.  Erratum to: A narrative review on the management of medication overuse headache: the steep road from experience to evidence , 2009, The Journal of Headache and Pain.

[54]  E. McCarthy,et al.  Complementary and Alternative Medicine Use Among Adults With Migraines/Severe Headaches , 2011, Headache.

[55]  M. de Tommaso,et al.  Fibromyalgia Comorbidity in Primary Headaches , 2009, Cephalalgia : an international journal of headache.

[56]  R. Lipton,et al.  Factors associated with the onset and remission of chronic daily headache in a population-based study , 2003, Pain.

[57]  S. Silberstein,et al.  Olanzapine in the Treatment of Refractory Migraine and Chronic Daily Headache , 2002, Headache.

[58]  N. Gadoth,et al.  Caffeine as a risk factor for chronic daily headache: A population-based study , 2005, Neurology.

[59]  K. Merikangas,et al.  Migraine and psychopathology. Results of the Zurich cohort study of young adults. , 1990, Archives of general psychiatry.

[60]  R. Lipton,et al.  Topiramate Treatment of Chronic Migraine: A Randomized, Placebo‐Controlled Trial of Quality of Life and Other Efficacy Measures , 2009, Headache.

[61]  R. Lipton,et al.  Efficacy and Safety of Topiramate for the Treatment of Chronic Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Trial , 2007, Headache.

[62]  R. Lipton,et al.  Tension-type Headache and Migraine in Multiple Sclerosis , 2010, Current pain and headache reports.

[63]  A. May,et al.  Use of Complementary and Alternative Medicine in Patients Suffering from Primary Headache Disorders , 2009, Cephalalgia : an international journal of headache.

[64]  R. Lipton,et al.  Rates, predictors, and consequences of remission from chronic migraine to episodic migraine , 2011, Neurology.

[65]  J. Benito-León,et al.  Gabapentin in the Treatment of SUNCT Syndrome , 2002, Headache.

[66]  S. Silberstein,et al.  Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine with/without aura in adults: a randomized, placebo-controlled, double-blind, 12-week pilot study. , 2006, Clinical therapeutics.

[67]  A. Srikiatkhachorn.  Chronic Daily Headache: A Scientist's Perspective , 2002, Headache.

[68]  E. Uzar,et al.  The effect of sodium valproate on chronic daily headache and its subgroups , 2008, The Journal of Headache and Pain.

[69]  V. Karpitskiy,et al.  Intravenous Valproate Sodium in the Treatment of Daily Headache , 2002, Headache.

[70]  R. Lipton,et al.  Migraine prevalence, disease burden, and the need for preventive therapy , 2007, Neurology.

[71]  J. Pascual.  Migraña crónica: tratamiento , 2012 .

[72]  H. Diener,et al.  OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial , 2010, Cephalalgia : an international journal of headache.

[73]  Jes Olesen,et al.  The International Classification of Headache Disorders: 2nd edition. , 2004, Cephalalgia : an international journal of headache.

[74]  P. Bacchetti,et al.  Clinic–based study of family history of vascular risk factors and migraine , 2005, The Journal of Headache and Pain.

[75]  N. Mathew.  Transformed migraine. , 1993, Cephalalgia : an international journal of headache.

[76]  S. Silberstein,et al.  A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis , 2002, Neurology.

[77]  P. Davies.  Medication overuse headache: A silent pandemic , 2012, PAIN.

[78]  J. Cramer,et al.  Comorbidities of epilepsy: Results from the Epilepsy Comorbidities and Health (EPIC) survey , 2011, Epilepsia.

[79]  Peng Liu,et al.  Acupuncture versus topiramate in chronic migraine prophylaxis: A randomized clinical trial , 2011, Cephalalgia : an international journal of headache.

[80]  M. Topcuoglu,et al.  Efficacy of Intravenous Magnesium Sulfate in the Treatment of Acute Migraine Attacks , 2001, Headache.

[81]  J. Saper.  The Mixed Headache Syndrome: A New Perspective , 1982, Headache.

[82]  G. Lorenzo,et al.  Prevalence, Pattern and Predictors of use of Complementary and Alternative Medicine (CAM) in Migraine Patients Attending a Headache Clinic in Italy , 2005, Cephalalgia : an international journal of headache.

[83]  M. M. Valença,et al.  Cefaléia de "difícil controle" ARTIGO ORIGINAL , 2003 .

[84]  S. Silberstein,et al.  Intravenous Propofol in the Treatment of Refractory Headache , 2002, Headache.

[85]  Shuu-Jiun Wang,et al.  Comorbidity profiles of chronic migraine sufferers in a national database in Taiwan , 2012, The Journal of Headache and Pain.

[86]  J. Miner,et al.  Olanzapine versus droperidol for the treatment of primary headache in the emergency department. , 2008, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[87]  R. Lipton,et al.  Classification of daily and near-daily headaches , 1996, Neurology.

[88]  R. Lipton,et al.  Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[89]  J. Speciali,et al.  Signs of Temporomandibular Disorders in Migraine Patients: A Prospective, Controlled Study , 2010, The Clinical journal of pain.

[90]  N. Santanello,et al.  Migraine and cardiovascular disease , 2010, Neurology.

[91]  R. Lipton.  Tracing transformation , 2009, Neurology.

[92]  S. Palmisani,et al.  Emerging treatment for chronic migraine and refractory chronic migraine , 2012, Expert opinion on emerging drugs.

[93]  H. Diener,et al.  Topiramate Reduces Headache Days in Chronic Migraine: A Randomized, Double-Blind, Placebo-Controlled Study , 2007, Cephalalgia : an international journal of headache.

[94]  Richard B. Lipton,et al.  Obesity is a risk factor for transformed migraine but not chronic tension-type headache , 2006, Neurology.

[95]  H. Diener,et al.  OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial , 2010, Cephalalgia : an international journal of headache.